Overview

Treatment Development of Triheptanoin (G1D)

Status:
Active, not recruiting
Trial end date:
2025-03-29
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD), as a percentage of calories consumed, of triheptanoin (C7 oil; C7) in a pediatric and adult patient population genetically diagnosed with glucose transporter type 1 deficiency disorder (G1D).
Phase:
Phase 1
Details
Lead Sponsor:
Juan Pascual
University of Texas Southwestern Medical Center
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)